biostudies-literatureUnknown10(9)Pascual TPfizer<h4>Background</h4>The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses.<h4>Patients and methods</h4>Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan-Meier curESMO open105572https://www.ebi.ac.uk/biostudies/studies/S-EPMC12424417biostudies-literaturePalbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.PMC12424417Pernas SAdamo BPrat AVillanueva LGonzalez-Rodriguez MGalvan PGonzalez-Farre XFerrero-Cafiero JMNuciforo PGalan MCanes JTolosa PCiruelos EGonzalez-Farre BVillacampa GOliveira MPerello AVillagrasa PMele MCortes JPascual TEscriva-de-Romani SMartinez EPare LfalsePalbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.<h4>Background</h4>The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses.<h4>Patients and methods</h4>Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan-Meier cur2025-01-01T00:00:00Z2025 Sep2026-06-03T07:44:16.161Z2026-04-26T03:09:47.076ZS-EPMC124244174089688010.1016/j.esmoop.2025.105572